Multiple clinical studies were conducted during the research effort, including six published studies. The published works demonstrate that ResQPOD offers a significant improvement in cardiac output and blood flow to the brain and in preventing shock in the event of considerable blood loss, when compared to conventional resuscitation. According to Advanced Circulatory Systems, data from the NASA studies played a major role in the company obtaining U.S. Food and Drug Administration 501K clearance for the device.
Dr. Keith Lurie, chief medical officer at Advanced Circulatory Systems and a primary member of the collaborative research effort, said, “The three-way partnership between NASA, private industry, and the U.S. Army Institute of Surgical Research is really a model for how organizations can work together to benefit both government programs and civilians.”
In 2006, Dr. Smith Johnston, the lead flight surgeon for NASA’s space shuttle missions, added ResQPOD to the list of medical equipment that is available for returning astronaut crews. The device was on hand for the landing of Space Shuttle Atlantis (STS-115) on September 21, 2006.
“We’re excited that our devices were available to the medical team [for the STS-115 mission] and look forward to continued collaboration with NASA to assist its efforts to safeguard the health of the astronauts,” added Lurie.
Manufactured commercially by Advanced Circulatory Systems and distributed by Sylmar, California-based Tri-anim Health Services Inc., the ResQPOD circulatory enhancer improves upon the standard of care for patients with a variety of clinical conditions associated with low blood flow. Advanced Circulatory Systems’ primary commercial focus, though, is on non-breathing patients who can benefit from enhanced circulation, such as those experiencing cardiac arrest.
According to the American Heart Association, about 900 Americans fall victim to sudden cardiac arrest every day, with approximately 95 percent dying before they reach the hospital. This is why cardiopulmonary resuscitation (CPR) can mean the difference between life and death, as increasing blood flow to the heart and brain until the heart can be restarted is critical to improving survival rates with normal neurological functioning.
ResQPOD is an American Heart Association-rated Class IIa impedance threshold device, meaning that it is the highest recommended “adjunct” in the association’s latest guidelines for CPR. As a Class IIa impedance threshold device, it also carries a higher recommendation than any medication used to boost circulation in adults suffering cardiac arrest, according to these guidelines.